Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock in a transaction on Friday, August 14th. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71. Following the transaction, the insider owned 18,630,739 shares in the company, valued at approximately $674,991,673.97. This trade represents a 1.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock traded up $1.13 during trading hours on Tuesday, hitting $37.37. The company’s stock had a trading volume of 6,409,504 shares, compared to its average volume of 5,396,372. The company has a market cap of $26.99 billion, a PE ratio of -70.51 and a beta of 1.12. The business has a 50 day moving average price of $34.16 and a two-hundred day moving average price of $30.17. Roivant Sciences Ltd. has a 12-month low of $11.54 and a 12-month high of $37.46.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. As a group, research analysts anticipate that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Citigroup boosted their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Finally, Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Institutional Trading of Roivant Sciences

A number of large investors have recently modified their holdings of ROIV. Fifth Third Bancorp increased its holdings in Roivant Sciences by 8.7% during the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after purchasing an additional 376 shares during the period. Bessemer Group Inc. grew its position in shares of Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after buying an additional 441 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after buying an additional 445 shares during the period. Versant Capital Management Inc increased its stake in shares of Roivant Sciences by 13.9% during the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock valued at $141,000 after buying an additional 487 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its holdings in shares of Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after acquiring an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.